Novo Nordisk A/S secured US FDA approval for its Wegovy pill (once-daily oral semaglutide, 25 mg), marking the first oral glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management in adults with obesity or overweight and at least one weight-related comorbidity. The decision also includes an indication to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke or cardiovascular death in adults with established cardiovascular disease and either obesity or overweight.

The approval was based on data from the Phase 3 OASIS 4 trial, in which adult participants receiving the oral semaglutide regimen achieved a mean weight reduction of 16.6 %, broadly in line with outcomes for injectable Wegovy dosage forms. In the study, approximately one in three participants attained ≥20 % weight loss, reaffirming both the efficacy and the well-characterized safety profile of semaglutide for weight management. Novo Nordisk expects to initiate commercial launch of the Wegovy pill in the US in early January 2026. The company has also filed for regulatory review of the oral semaglutide weight-management indication with the European Medicines Agency (EMA) and other international regulators.

Clinical context

Market analysts expect oral agents to capture a meaningful share of the obesity treatment market in the latter half of this decade, as pricing, scalability, and patient convenience become increasingly important drivers of prescribing behaviour. Novo Nordisk’s approval therefore places the company at the forefront of intensifying competition among major pharmaceutical players seeking to commercialise oral weight-loss therapies.

Eli Lilly is the most advanced challenger, with orforglipron, a small-molecule oral GLP-1 receptor agonist, having completed Phase 3 development and entering regulatory review in late 2025. Structure Therapeutics is advancing aleniglipron (GSBR-1290), another small-molecule oral GLP-1 receptor agonist, through Phase 2, with Phase 3 studies planned for 2026. Novo Nordisk is also progressing amycretin, an oral unimolecular GLP-1 and amylin agonist, with Phase 3 development under preparation following encouraging mid-stage data. Elsewhere, Viking Therapeutics’ oral GLP-1/GIP dual agonist VK2735 and Regor Therapeutics’ RGT-075 remain in Phase 2 development, while Roche, through Carmot Therapeutics, is evaluating CT-996, a once-daily oral small-molecule GLP-1 receptor agonist, in early Phase 1 trials.

Together, these programmes underscore the rapid evolution of the oral obesity pipeline, with multiple mechanisms and molecular formats now converging on a market historically dominated by injectable therapies.